Panel also voted 10-1, stating the risks of MDMA use outweigh the benefits for PTSD treatment.
Lykos Therapeutics expressed disappointment in the vote, aiming to address FDA questions for potential future approval of MDMA therapy.
PTSD symptoms include flashbacks, increased heart rate, avoidance of triggers, difficulty relaxing, irritability, sleep issues, and social withdrawal.
[
Collection
]
[
|
...
]